McNeil's Vascor (bepridil)
Executive Summary
Classified by FDA as a "1B" drug (a new molecular entity with a modest therapeutic gain over existing therapies), not a "1C" drug as originally announced by FDA ("The Pink Sheet" Jan. 7, p. 4 and p. 9). Vascor will be co-promoted by McNeil and Carter- Wallace. Carter-Wallace will not be promoting bepridil under the name Bepadin, as was reported in "The Pink Sheet" (Jan. 7, p. 4).